Lung Cancer

There were many advances in lung cancer targeted treatments in 2014. The one that most excites Dr. Geoffrey Oxnard from Dana-Farber Cancer Institute is the use of liquid biopsies.

[powerpress]

An annual tradition is a reflection on the key developments in the field over the past year. This year saw some major advances, with several of the biggest changes bubbling just below the surface and about to really break out in 2015.  So without further adieu, here's my list.

For those who wish to access the pdf, it's here: Top 5 Highlights in Lung Cancer 2014

Agree? Disagree? What's highest on your wish list for 2015?

It may not be the biggest present lung cancer patients could get for the holiday season, but the FDA just yesterday approved Cyramza (ramucirimab), an anti-angiogenic antibody with a mechanism similar to Avastin (bevacizumab) that is already approved for gastric cancer, as a new agent to treat previously treated advanced NSCLC, any histology. This was based on the phase III randomized trial called REVEL that was presented at ASCO 2014, so let's review the evidence that led to this approval. 

I have lived with lung cancer since 2005. On this "Giving Tuesday," I ask that you join me in making an end-of-year donation to an organization that truly deserves it, the Global Resource for Advancing Cancer Education (GRACE).

Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, gives thanks to GRACE and urges others to do the same.

I was diagnosed with non-small cell lung cancer in April 2005. I was only 45 years old, I had never smoked, and I thought lung cancer wasn’t something I would ever have to worry about. Now I know that upward of 15 percent of lung cancer patients are never smokers.

Three years after my initial diagnosis, doctors discovered I had the ALK mutation. I had no idea what that meant or that I would even still be talking about it in 2014. In fact, I was seeing a psychologist to prepare for my death.

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

[powerpress]

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jared Weiss, GRACE Vice President, and his patient Tomma Hargraves, discuss how they became a team.

Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.